- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- olaparib, abiraterone acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 862
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
- Interventions
- Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1305/BNT325, Pembrolizumab, BNT327
- Drug · Combination Product
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 42
- States / cities
- Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
- Conditions
- Prostate Cancer
- Interventions
- licorice root extract, docetaxel
- Dietary Supplement · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
- Interventions
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Drug
- Lead sponsor
- Modra Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Portland, Oregon + 1 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Dasatinib, Docetaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Springfield, Illinois • Nyack, New York + 2 more
- Conditions
- PROSTATE CANCER
- Interventions
- Docetaxel and Prednisone, Radiation Therapy
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Prostate Cancer
- Interventions
- High dose testosterone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 18F-fluciclovine PET Scan
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 18 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Prostate Cancer Metastatic
- Interventions
- ARV-110
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 54
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 51 more
- Conditions
- Prostatic Neoplasms
- Interventions
- CP-751,871, docetaxel, prednisone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Seviteronel: given orally once daily in 28-day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Erdafitinib
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Bevacizumab, Lenalidomide, Docetaxel, Prednisone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- Paclitaxel polyglumex (Xyotax)
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Denosumab, Enzalutamide, Abiraterone, Prednisone
- Biological · Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Prostatic Neoplasms
- Interventions
- MVA 5T4, Docetaxel
- Biological · Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Carboplatin, 177Lu-PSMA-617
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
- Conditions
- Prostate Cancer
- Interventions
- Cancer Macrobead placement in abdominal cavity
- Biological
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- carboplatin, RAD 001, prednisone, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Evanston, Illinois • Detroit, Michigan • Farmington Hills, Michigan + 1 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Standard ADT, Dovitinib
- Drug
- Lead sponsor
- Oscar Goodman, Jr.
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada